98%
921
2 minutes
20
Next-generation sequencing (NGS) has become a powerful sequencing tool, applied in a wide range of biological studies. However, the traditional sample preparation protocol for NGS is non-strand-specific (NSS), leading to biased estimates of expression for transcripts overlapped at the antisense strand. Strand-specific (SS) protocols have recently been developed. In this study, we prepared the same RNA sample by using the SS and NSS protocols, followed by sequencing with Illumina HiSeq platform. Using real-time quantitative PCR as a standard, we first proved that the SS protocol more precisely estimates gene expressions compared with the NSS protocol, particularly for those overlapped at the antisense strand. In addition, we also showed that the sequence reads from the SS protocol are comparable with those from conventional NSS protocols in many aspects. Finally, we also mapped a fraction of sequence reads back to the antisense strand of the known genes, originally without annotated genes located. Using sequence assembly and PCR validation, we succeeded in identifying and characterizing the novel antisense genes. Our results show that the SS protocol performs more accurately than the traditional NSS protocol and can be applied in future studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393923 | PMC |
http://dx.doi.org/10.1155/2015/182389 | DOI Listing |
Rinsho Ketsueki
September 2025
Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Faculty of life Sciences.
Adult T-cell leukemia-lymphoma (ATL) is a malignancy of peripheral CD4+ T cells induced by human T-cell leukemia virus type 1 (HTLV-1). HTLV-1 encodes two oncogenic viral factors, Tax and HTLV-1 bZIP factor (HBZ) in the sense and antisense strands of the provirus respectively. Both Tax and HBZ dysregulate the expression and activities of a large number of host genes and cellular signaling pathways via their multimodal functions.
View Article and Find Full Text PDFJ Chromatogr A
August 2025
Synthetic Molecule Pharmaceutical Sciences, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address:
Chemical modifications have enabled the use of oligonucleotides as therapeutic drugs. However, they also complicate their analytical characterization. Phosphorothioate (PS)-modified oligonucleotides exist as complex mixtures of diastereomers.
View Article and Find Full Text PDFEMBO Rep
September 2025
Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, 90187, Umeå, Sweden.
Long noncoding RNAs (lncRNAs) are emerging as key regulatory players of coding gene expression in eukaryotes. Here, we investigate the roles of the lncRNAs SVALKA (SVK) and SVALNA (SVN) in regulating CBF1 and CBF3 gene expression in Arabidopsis under cold stress conditions. We integrated omics approaches, together with genetics and molecular biology, to uncover the transcriptional dynamics and regulatory mechanisms of SVK and SVN.
View Article and Find Full Text PDFMethods Mol Biol
August 2025
Division of Cancer Medicine, Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Small interfering RNAs (siRNAs) hold significant promise as therapeutic agents for treating human diseases. However, their use is often limited by unintended off-target effects arising from both the sense and antisense strands. Since the 5'-phosphate group on either strand is necessary for recognition by Argonaute 2 (AGO2), the core protein in the RNA-induced silencing complex (RISC), blocking phosphorylation of the sense strand may prevent its incorporation into RISC, thereby reducing potential off-target effects.
View Article and Find Full Text PDFBioanalysis
August 2025
Drug Metabolism and Pharmacokinetics, Biogen, Cambridge, MA, USA.
Hybridization-based LC-MS is rapidly emerging as a bioanalytical platform for oligonucleotides, particularly when both high sensitivity and high specificity are needed. When used to analyze single-stranded antisense oligonucleotide (ASO) therapeutics, the workflows are relatively well established, but the analysis of double-stranded small interfering RNA (siRNA) therapeutics presents additional challenges due to competition for binding from the sense strand. In the last two years, the authors have independently published extensively on hybridization-based LC-MS bioanalysis of siRNA therapeutics, and now we take a step back to evaluate the progress we have made and offer our thoughts on the future of this platform.
View Article and Find Full Text PDF